,3,4 Although the FDA recently approved the AKT inhibitor capivasertib in combination with the estrogen receptor antagonist fulvestrant for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in patients whose tumors harbor alterations in PIK3CA, AKT1, or PTEN,29 clinical trials investigating pharmacological AKT inhibitors in melanoma have shown limited efficacy.6 This evidence concerns the gene AKT1 and melanoma.